XOMA 213

Drug Profile

XOMA 213

Alternative Names: LFA102; X 213; XOMA-213

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator XOMA
  • Developer Novartis; XOMA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prolactinoma
  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 20 Mar 2017 XOMA 213 is available for licensing as of 16 Mar 2017. http://www.xoma.com/index.htm
  • 24 Feb 2017 XOMA completes a phase II trial for Suppression of lactation in Spain (EudraCT2015-005751-27)
  • 18 May 2016 XOMA initiates enrolment in a phase II trial for Suppression of lactation in Spain (EudraCT2015-005751-27; 9198651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top